糖尿病并发症影响美国老年患者HbA1c治疗目标的成本效益分析
研究基于2011-2016年NHANES数据构建具有不同健康状态的美国老年糖尿病代表性亚组,使用CDC-RTI国际糖尿病成本效益模型评估严格目标(HbA1c<7.5%)与中等目标(HbA1c<8.5%)的长期健康与经济后果。结果显示严格目标对无并发症或仅微血管并发症者平均具有成本效益,但对有大血管并发症或预期寿命不足7年者不具有成本效益。
要点
- 严格HbA1c目标对无并发症或仅微血管并发症的老年糖尿病患者具有成本效益
- 合并大血管并发症时严格目标成本效益差,每QALY均超过$82,413
- 预期寿命不足7年时严格目标不具有成本效益
核心结论
- 从成本效益角度看,老年糖尿病患者的血糖目标应综合考虑并发症复杂性和预期寿命,支持指南推荐。
研究设计与样本
- 基于2011-2016年NHANES数据生成全国代表性的老年糖尿病健康状态亚组,使用CDC-RTI国际糖尿病成本效益模型模拟终身健康与成本。
- 模拟人群中每个健康亚组个体均具有平均特征,未考虑个体水平变异;研究从卫生系统视角开展,以每QALY $50,000为增量成本效益阈值。
主要发现
- 严格目标(HbA1c<7.5%)对无并发症者平均每QALY成本为$10,007,对仅微血管并发症(除外肾衰竭)者为$19,621。
- 严格目标对有一个或多个大血管并发症者每QALY成本均超过$82,413,不具有成本效益。
- 严格目标在个体剩余寿命不足7年时不具有成本效益。
关键数值与推荐
- 严格血糖控制目标定义为HbA1c<7.5%,中等控制目标定义为HbA1c<8.5%。
- 增量成本效益阈值采用每质量调整生命年(QALY)$50,000。
临床怎么用
- 对于无并发症或仅微血管并发症的老年糖尿病患者,可考虑严格HbA1c目标(<7.5%)以获取成本效益。
- 对于合并大血管并发症或预期寿命不足7年的老年患者,应避免过于严格的HbA1c目标,选择中等目标(<8.5%)更符合成本效益。
局限性
- 模拟人群使用亚组平均特征,未考虑个体水平变异,可能限制结果的个体化外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Guidelines on the standard care of diabetes recommend that glycemic treatment goals for older adults consider the patient's complications and life expectancy. In this study, we examined the influence of diabetes complications and associated life expectancies on the cost-effectiveness (CE) of HbA1c treatment goals. RESEARCH DESIGN AND METHODS: We used data from the 2011-2016 National Health and Nutrition Examination Survey (NHANES) to generate nationally representative subgroups of older individuals with diabetes with various health states. We used the Centers for Disease Control and Prevention-RTI International diabetes CE model to estimate the long-term consequences of two treatment goals-a stringent control goal (HbA1c <7.5%) and a moderate control goal (HbA1c <8.5%)-on health and cost. Our simulation population represented typical patients, and all individuals in each health subgroup had average characteristics, which did not account for person-level variations. The CE study was conducted from a health system perspective and followed the study samples over a lifetime. We used $50,000 per quality-adjusted life year (QALY) as the incremental CE threshold. RESULTS: A stringent goal was, on average, cost-effective for individuals with no complications ($10,007 per QALY) or only microvascular complications (excluding renal failure; $19,621 per QALY), but it was not cost-effective for individuals with one or more macrovascular complications (all >$82,413 per QALY). Further, a stringent goal was not cost-effective when an individual had less than 7 years of life remaining. CONCLUSIONS: Our findings support the guideline recommendation that glycemic goals for older adults should consider the complexity of their complications and their life expectancy from a CE perspective.
引用
- Shao H, Lin J, Zhuo X, et al. Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. Diabetes Care. 2019. PMID: 31530661. doi:10.2337/dc19-0381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。